Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT02695953

Neurobiology of Posttraumatic Stress Disorder Dysfunction and Recovery Following Cognitive Processing Therapy

Posttraumatic stress disorder (PTSD) is a significant personal and societal burden. The purpose of this study is to examine genetic, epigenetic, behavioral, and brain activity changes related to PTSD dysfunction and recovery before and after treatment with Cognitive Processing Therapy.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

McLean Hospital

Belmont, Massachusetts, 02478, United States

About this study

Using functional magnetic resonance imaging approaches, the present research aims to examine the relationship between traumatic experience and the neural mechanisms of various PTSD symptoms, and determine how this relationship changes during PTSD extinction. Also, this proposal aims to better understand how the genetic/epigenetic profile of several genes predicts, and perhaps changes, in response to recovery from PTSD along with its neural correlates. This understanding will help identify individuals who will respond most optimally to a specific empirically based PTSD treatment, Cognitive Processing Therapy, while further connecting genetic biomarkers of risk with neural intermediate phenotypes underlying PTSD symptomatology.This study is observational as the investigator does not assign specific interventions to the participants of the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • PTSD diagnosis, as measured by the Clinician Administered PTSD Scale for DSM-5
  • history of chronic childhood trauma due to relational abuse
  • Ability to understand and sign informed consent
  • Enrollment in CPT program at McLean Hospital
  • Both genders, all ethnic backgrounds, age between 18 and 55
  • Fluent English speakers
  • Normal or Corrected Vision

Exclusion criteria

  • History or current schizophrenia spectrum disorder or other psychotic disorders
  • History or current bipolar or other related disorders
  • Alcohol and/or substance use disorder within the past month
  • Metal implants
  • Medical or neurological illness (e.g., seizures, head injury in which they experienced a loss of consciousness)
  • Positive pregnancy test

Treatment and study plan

Primary outcomes

  1. Potential Change in Evidence of PTSD symptoms with neuroimaging

    Time frame: Within 30 days before and again within 30 days after Cognitive Processing Therapy Treatment.

Sponsors and collaborators

Lead sponsor

Milissa Kaufman

Other

Registry information

Important dates

Study start
2016
Primary completion
2027
Study completion
2027
First posted
Mar 2, 2016
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.